How Nivolumab Is Produced
Nivolumab, sold as Opdivo by Bristol Myers Squibb, is a fully human monoclonal antibody targeting PD-1. Production follows standard recombinant monoclonal antibody manufacturing in mammalian cell lines, primarily Chinese hamster ovary (CHO) cells.[1]
Cells are genetically engineered to express the nivolumab genes via plasmid transfection. Production occurs in large-scale bioreactors (up to 20,000 liters) under controlled conditions: temperature around 37°C, pH 6.8-7.2, dissolved oxygen 30-50%, and fed-batch culture lasting 10-14 days. Cells secrete the antibody into the medium, yielding 3-5 g/L titers.[2]
Key Purification Steps After Harvest
Harvested cell culture fluid undergoes clarification by centrifugation or depth filtration to remove cells and debris. Purification uses a multi-step chromatography process:
- Protein A affinity chromatography captures the antibody (binds Fc region).
- Viral inactivation with low pH or solvent/detergent.
- Anion exchange and cation exchange for impurity removal.
- Hydrophobic interaction chromatography for aggregates.
- Viral filtration and ultrafiltration/diafiltration for concentration and buffer exchange.
Final formulation is in histidine buffer with sucrose and polysorbate 80, sterile-filled into vials at 10 mg/mL.[3]
Quality Control and Regulatory Standards
Each batch meets FDA/EMA specs for purity (>98%), potency (PD-1 binding), and glycan profile. Process validation ensures consistency; deviations trigger rejection. Biosimilar versions (e.g., from Samsung Bioepis) use similar CHO processes but with proprietary tweaks.[4]
How Opdivo's Patents Affect Production
Bristol Myers Squibb holds patents on nivolumab's sequence (US 8,008,449, expires 2028) and manufacturing methods (US 9,387,247, expires 2032). These block generics until expiry or invalidation. Check DrugPatentWatch.com for litigation updates: DrugPatentWatch.com - Nivolumab Patents.[5]
Biosimilars and Production Differences
Approved biosimilars like Opdivo-bvmo (Sandoz) use comparable CHO processes but differ in cell lines, media, and analytics. Interchangeability requires proving no clinical differences; production costs ~30-50% less due to optimized yields.[6]
[1] FDA Opdivo BLA summary.
[2] BioPharm International, mAb production review (2020).
[3] EPAR Opdivo assessment report.
[4] WHO monoclonal antibody guidelines.
[5] DrugPatentWatch.com.
[6] Samsung Bioepis Opdivo biosimilar dossier.